Figure 4

Intravenous C16 and Ang-1 enhanced the efficacy of PMSC therapy for inhibiting reactive astrogliosis in the EAE rat model. (A–N) Immunofluorescence staining of brain cortex and spinal cord specimens for the astrocyte marker GFAP (red) at 3 and 8 weeks pi. SC denotes transverse sections through the anterior horn of the lumbar spine, and BC denotes coronal sections of the motor cortex. (O–R) Immunofluorescence staining of the PMSC grafts (green) for GFAP (red). Scale bar = 100 μm. (S,T) Relative areas of GFAP staining at 3 (S) and 8 (T) weeks pi. n = 5, ^#P < 0.05 vs. normal, ^*P < 0.05 vs. vehicle, ^&P < 0.05 vs. PMSCs. (S) In SC, PMSCs vs. vehicle: ES = 0.15, P = 0.0003; P + C + A vs. vehicle: ES = 0.22, P < 0.0001; P + C + A vs. PMSCs: ES = 0.9, P < 0.0001. In BC, PMSCs vs. vehicle: ES = 0.18, P = 0.0002; P + C + A vs. vehicle: ES = 0.21, P = 0.0001; P + C + A vs. PMSCs: ES = 0.25, P = 0.0016. (T) In SC, PMSCs vs. vehicle: ES = 0.49, P < 0.0001; P + C + A vs. vehicle: ES = 0.56, P < 0.0001; P + C + A vs. PMSCs: ES = 0.52, P < 0.0001. In BC, PMSCs vs. vehicle: ES = 0.64, P < 0.0001; P + C + A vs. vehicle: ES = 0.85, P < 0.0001; P + C + A vs. PMSCs: ES = 0.16, P = 0.0005.